DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Raised to $14.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target hoisted by Robert W. Baird from $12.00 to $14.00 in a research note issued to investors on Friday,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical instruments supplier’s stock.

Other analysts also recently issued research reports about the company. UBS Group lowered their price objective on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Mizuho lifted their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Barrington Research reiterated an “outperform” rating and set a $14.00 price target on shares of DENTSPLY SIRONA in a report on Monday, January 5th. JPMorgan Chase & Co. dropped their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Finally, Barclays began coverage on shares of DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus target price of $14.00.

DENTSPLY SIRONA Stock Performance

DENTSPLY SIRONA stock opened at $14.68 on Friday. The firm has a fifty day simple moving average of $12.42 and a two-hundred day simple moving average of $12.47. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a twelve month low of $9.85 and a twelve month high of $17.34. The company has a market capitalization of $2.93 billion, a PE ratio of -4.89, a P/E/G ratio of 1.19 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. During the same quarter in the prior year, the firm posted $0.26 EPS. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts expect that DENTSPLY SIRONA will post 1.84 EPS for the current year.

DENTSPLY SIRONA Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were issued a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 annualized dividend and a yield of 4.4%. DENTSPLY SIRONA’s dividend payout ratio is -21.33%.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier sold 82,200 shares of DENTSPLY SIRONA stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.52% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Eurizon Capital SGR S.p.A. bought a new stake in DENTSPLY SIRONA during the 4th quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $26,000. Parkside Financial Bank & Trust boosted its position in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 1,477 shares in the last quarter. Huntington National Bank grew its stake in DENTSPLY SIRONA by 292.9% in the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,077 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,122 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.